David J. Maron

Cardiologist

Clinical Professor, Medicine - Cardiovascular Medicine
Dr. Maron is Director of Preventive Cardiology. He is board certified in internal medicine, cardiovascular disease, and clinical lipidology. He was an undergraduate at Stanford, received his medical degree from University of Southern California, and completed his residency in internal medicine at UCLA. He completed a cardiology fellowship and a research fellowship in cardiovascular disease epidemiology and prevention at Stanford University as a Robert Wood Johnson Clinical Scholar. He was on the faculty at Vanderbilt for 20 years before returning to Stanford in 2014.

Preventive Cardiology

  • 300 Pasteur Drive
  • Stanford, CA 94305
  • Phone: 650-723-6459
Learn More About the Clinic Getting Here Make An Appointment

Professional Education

Medical Education: Univ Of So Ca - Los Angeles (6/4/1981) CA

Internship: UCLA Health Sciences (06/23/1982) CA

Residency: UCLA Health Sciences (6/30/1984) CA

Residency: Stanford University Hospital -Internal Medicine Residency Training Program (6/30/1986) CA

Fellowship: Stanford University - Cardiovascular Medicine (6/30/1991) CA

Board Certification: Cardiovascular Disease, American Board of Internal Medicine (1991)

Board Certification: Internal Medicine, American Board of Internal Medicine

Clinical Trials

Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you have access to the latest, advanced clinical trials.

Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.

Prognostic Value of Fasting Versus Nonfasting Low-Density Lipoprotein Cholesterol Levels on Long-Term Mortality: Insight From the National Health and Nutrition Examination Survey III (NHANES-III).
Doran, B., Guo, Y., Xu, J., Weintraub, H., Mora, S., & Bangalore, S. (2014). Prognostic Value of Fasting Versus Nonfasting Low-Density Lipoprotein Cholesterol Levels on Long-Term Mortality: Insight From the National Health and Nutrition Examination Survey III (NHANES-III). Circulation, 130(7), 546-553.

Trial to Assess Chelation Therapy (TACT) and equipoise: When evidence conflicts with beliefs.
Maron, D. J., & Hlatky, M. A. (2014). Trial to Assess Chelation Therapy (TACT) and equipoise: When evidence conflicts with beliefs. American heart journal, 168(1), 4-5.

Comparative Definitions for Moderate-Severe Ischemia in Stress Nuclear, Echocardiography, and Magnetic Resonance Imaging
Shaw, L. J., Berman, D. S., Picard, M. H., Friedrich, M. G., Kwong, R. Y., & Douglas, P. S. (2014). Comparative Definitions for Moderate-Severe Ischemia in Stress Nuclear, Echocardiography, and Magnetic Resonance Imaging. JACC-CARDIOVASCULAR IMAGING, 7(6), 593-604.

As REGARDS treatment goal attainment compared with COURAGE: the perfect should not be the enemy of the good.
Maron, D. J., & Boden, W. E. (2014). As REGARDS treatment goal attainment compared with COURAGE: the perfect should not be the enemy of the good. Journal of the American College of Cardiology, 63(16), 1634-1635.

Low Levels of High-Density Lipoprotein Cholesterol and Increased Risk of Cardiovascular Events in Stable Ischemic Heart Disease Patients A Post-Hoc Analysis From the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation)
Acharjee, S., Boden, W. E., Hartigan, P. M., Teo, K. K., Maron, D. J., & Weintraub, W. S. (2013). Low Levels of High-Density Lipoprotein Cholesterol and Increased Risk of Cardiovascular Events in Stable Ischemic Heart Disease Patients A Post-Hoc Analysis From the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation). JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 62(20), 1826-1833.

Frequency, Predictors, and Consequences of Crossing Over to Revascularization Within 12 Months of Randomization to Optimal Medical Therapy in the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) Trial
Spertus, J. A., Maron, D. J., Cohen, D. J., Kolm, P., Hartigan, P., & Mancini, G. Bj. (2013). Frequency, Predictors, and Consequences of Crossing Over to Revascularization Within 12 Months of Randomization to Optimal Medical Therapy in the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) Trial. CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 6(4), 409-418.

Baseline stress myocardial perfusion imaging results and outcomes in patients with stable ischemic heart disease randomized to optimal medical therapy with or without percutaneous coronary intervention
Shaw, L. J., Weintraub, W. S., Maron, D. J., Hartigan, P. M., Hachamovitch, R., & Berman, D. S. (2012). Baseline stress myocardial perfusion imaging results and outcomes in patients with stable ischemic heart disease randomized to optimal medical therapy with or without percutaneous coronary intervention. AMERICAN HEART JOURNAL, 164(2), 243-250.

Is cardiac catheterization necessary before initial management of patients with stable ischemic heart disease? Results from a Web-based survey of cardiologists
Maron, D. J., Stone, G. W., Berman, D. S., Mancini, G. Bj., Scott, T. A., & Spertus, J. A. (2011). Is cardiac catheterization necessary before initial management of patients with stable ischemic heart disease? Results from a Web-based survey of cardiologists. AMERICAN HEART JOURNAL, 162(6), 1034-U124.

Angiographic Disease Progression and Residual Risk of Cardiovascular Events While on Optimal Medical Therapy Observations From the COURAGE Trial
Mancini, G. Bj., Hartigan, P. M., Bates, E. R., Sedlis, S. P., Maron, D. J., & Boden, W. E. (2011). Angiographic Disease Progression and Residual Risk of Cardiovascular Events While on Optimal Medical Therapy Observations From the COURAGE Trial. CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 4(6), 545-552.

Impact of Metabolic Syndrome and Diabetes on Prognosis and Outcomes With Early Percutaneous Coronary Intervention in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) Trial
Maron, D. J., Boden, W. E., Spertus, J. A., Hartigan, P. M., Mancini, G. Bj., & O'Rourke, R. A. (2011). Impact of Metabolic Syndrome and Diabetes on Prognosis and Outcomes With Early Percutaneous Coronary Intervention in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) Trial. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 58(2), 131-137.

Intensive Multifactorial Intervention for Stable Coronary Artery Disease Optimal Medical Therapy in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) Trial
Maron, D. J., Boden, W. E., O'Rourke, R. A., Hartigan, P. M., Calfas, K. J., & Teo, K. K. (2010). Intensive Multifactorial Intervention for Stable Coronary Artery Disease Optimal Medical Therapy in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) Trial. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 55(13), 1348-1358.

Impact of an Initial Strategy of Medical Therapy Without Percutaneous Coronary Intervention in High-Risk Patients From the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) Trial
Maron, D. J., Spertus, J. A., Mancini, G. Bj., Hartigan, P. M., Sedlis, S. P., & Boden, W. E. (2009). Impact of an Initial Strategy of Medical Therapy Without Percutaneous Coronary Intervention in High-Risk Patients From the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) Trial. AMERICAN JOURNAL OF CARDIOLOGY, 104(8), 1055-1062.

Effect of PCI on quality of life in patients with stable coronary disease
Weintraub, W. S., Spertus, J. A., Kolm, P., Maron, D. J., Zhang, Z., & Boden, W. E. (2008). Effect of PCI on quality of life in patients with stable coronary disease. NEW ENGLAND JOURNAL OF MEDICINE, 359(7), 677-687.

Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden - Results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy
Shaw, L. J., Berman, D. S., Maron, D. J., Mancini, J., Hayes, S. W., & Boden, W. E. (2008). Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden - Results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. CIRCULATION, 117(10), 1283-1291.

Optimal medical therapy with or without PCI for stable coronary disease
Boden, W. E., O'Rourke, R. A., Teo, K. K., Hartigan, P. M., Maron, D. J., & Mathien, J. (2007). Optimal medical therapy with or without PCI for stable coronary disease. NEW ENGLAND JOURNAL OF MEDICINE, 356(15), 1503-1516.

EFFECTS OF INTENSIVE MULTIPLE RISK FACTOR REDUCTION ON CORONARY ATHEROSCLEROSIS AND CLINICAL CARDIAC EVENTS IN MEN AND WOMEN WITH CORONARY-ARTERY DISEASE - THE STANFORD-CORONARY-RISK-INTERVENTION-PROJECT (SCRIP)
Haskell, W. L., Alderman, E. L., Fair, J. M., Maron, D. J., Mackey, S. F., & Farquhar, J. W. (1994). EFFECTS OF INTENSIVE MULTIPLE RISK FACTOR REDUCTION ON CORONARY ATHEROSCLEROSIS AND CLINICAL CARDIAC EVENTS IN MEN AND WOMEN WITH CORONARY-ARTERY DISEASE - THE STANFORD-CORONARY-RISK-INTERVENTION-PROJECT (SCRIP). CIRCULATION, 89(3), 975-990.

SATURATED FAT INTAKE AND INSULIN RESISTANCE IN MEN WITH CORONARY-ARTERY DISEASE
Maron, D. J., Fair, J. M., & Haskell, W. L. (1991). SATURATED FAT INTAKE AND INSULIN RESISTANCE IN MEN WITH CORONARY-ARTERY DISEASE. CIRCULATION, 84(5), 2020-2027.